References
- Sumitovant Biopharma created and launched as Sumitomo Dainippon Pharma and Roivant Sciences close transaction for strategic alliance. www.prnewswire.com/news-releases/sumitovant-biopharma-created-and-launched-as-sumitomo-dainippon-pharma-and-roivant-sciences-close-transaction-for-strategic-alliance-300979738.html
- Sumitovant Biopharma's website. www.sumitovant.com/
- Roivant Sciences website. https://roivant.com/#pipeline
- Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion. www.sanofi.com/en/media-room/press-releases/2019/2019-12-09-07-00-00
- Synthorx website. https://synthorx.com/
- Sanofi completes $4.8-Billion Ablynx acquisition. www.pharmtech.com/sanofi-completes-48-billion-ablynx-acquisition
- Astellas strengthens immuno-oncology pipeline with acquisition of Xyphos Biosciences, Inc. www.astellas.com/en/news/15516
- Xyphos Biosciences' website. https://xyphosinc.com/
- Neurocrine Biosciences and Xenon Pharmaceuticals announce agreement to develop first-in-class treatments for epilepsy. www.prnewswire.com/news-releases/neurocrine-biosciences-and-xenon-pharmaceuticals-announce-agreement-to-develop-first-in-class-treatments-for-epilepsy-300967168.html
- Xenon Pharmaceuticals website. https://www.xenon-pharma.com/
- Xenon Pharmaceuticals Inc . Pharmacokinetics of XEN901, a novel, selective NaV1.6 sodium channel inhibitor for the treatment of SCN8A-related epilepsy. American Epilepsy Society (AES) Annual Meeting. (2019). www.xenon-pharma.com/wp-content/uploads/2019/12/15-XEN901_Poster_72x42-FINALiii.pdf
- Denovo Biopharma licenses global rights to a novel late-stage oncology drug from Sunesis Pharmaceuticals. www.prnewswire.com/news-releases/denovo-biopharma-licenses-global-rights-to-a-novel-late-stage-oncology-drug-from-sunesis-pharmaceuticals-300970767.html
- Denovo Biopharma's website. www.denovobiopharma.com/index.html
- PharmaMar and Jazz Pharmaceuticals sign exclusive license agreement for lurbinectedin in the U.S. www.prnewswire.com/news-releases/pharmamar-and-jazz-pharmaceuticals-sign-exclusive-license-agreement-for-lurbinectedin-in-the-us-300977579.html
- PharmaMar website. http://pharmamar.com/about-pharmamar-2/?lang=en
- FDA . FDA approves new type of therapy to treat advanced urothelial cancer. www.fda.gov/news-events/press-announcements/fda-approves-new-type-therapy-treat-advanced-urothelial-cancer
- FDA grants accelerated approval to Astellas' and Seattle Genetics' PADCEV™ (enfortumab vedotin-ejfv) for people with locally advanced or metastatic urothelial cancer, the most common type of bladder cancer. www.astellas.com/en/news/15511
- FDA . Entry for Padcev on drugs@FDA. www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process
- SPRAVATO® (esketamine) nasal spray approved in europe for adults with treatment-resistant major depressive disorder. https://www.businesswire.com/news/home/20191219005272/en/SPRAVATO®-Esketamine-Nasal-Spray-Approved-Europe-Adults
- EMA . Summary of product characteristics for Spravato® 28mg nasal spray, solution. www.ema.europa.eu/en/documents/product-information/spravato-epar-product-information_en.pdf
- EMA . Spravato® 28mg nasal spray. www.ema.europa.eu/en/medicines/human/EPAR/spravato
- FDA . Entry for Spravato® on [email protected]. www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211243
- Sanders L . In 2019, a ketamine-based antidepressant raised hopes and concerns. ScienceNews. (2019). www.sciencenews.org/article/ketamine-based-depression-drugs-top-science-stories-2019-yir
- Ardelyx Announces positive topline results from pivotal Phase III PHREEDOM study evaluating tenapanor in CKD patients on dialysis. www.prnewswire.com/news-releases/ardelyx-announces-positive-topline-results-from-pivotal-phase-3-phreedom-study-evaluating-tenapanor-in-ckd-patients-on-dialysis-300967928.html
- Ardelyx website. https://ardelyx.com/what-we-do/
- Biohaven achieves positive topline results in pivotal Phase II/III study of vazegepant, the first and only intranasal CGRP receptor antagonist in clinical development for the acute treatment of migraine. www.biohavenpharma.com/investors/news-events/press-releases/12-17-2019
- Biohaven Pharmaceuticals website. https://www.biohavenpharma.com/about-biohaven
- Edvinsson L , HaanesKA , WarfvingeK , KrauseDN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat. Rev. Neurol.14(6), 338–350 (2018).
- Biohaven's NURTEC™ ODT (rimegepant) receives FDA approval for the acute treatment of migraine in adults. www.biohavenpharma.com/investors/news-events/press-releases/02-27-2020
- Aptar Pharma website, product solutions, UDS. https://pharma.aptar.com/en-us/dispensing-solutions/uds.html
- Positive top-line results from Phase I/II trial with intralymphatic Diamyd®. www.diamyd.com/docs/pressClips.aspx?ClipID=3523828
- Diamyd Medical website. https://www.diamyd.com/
- Towns R , PietropaoloM. GAD65 autoantibodies and its role as biomarker of Type 1 diabetes and latent autoimmune diabetes in adults (LADA). Drugs Future36(11), 847 (2011).
- Aphios granted US patent for oral administration of bryostatin-1 nanoparticles for treatment of neurodegenerative diseases. https://aphios.com/about/press-releases/aphios-granted-us-patent-for-oral-administration-of-bryostatin-1-nanoparticles-for-treatment-of-neurodegenerative-diseases/
- US Patent No : 10485766. (2019).
- Aphios Corporation website. https://aphios.com/about/company-overview/